Advanced search
Publication Cover
Future Medicinal Chemistry Volume 7, 2015 - Issue 16
Submit an article Journal homepage
979
Views
2
CrossRef citations to date
0
Altmetric
Review

Oligonucleotide Therapeutics: Chemistry, Delivery and Clinical Progress

Vivek K Sharma1 Department of Chemistry & Institute for Life Sciences, University of Southampton, Highfield, Southampton, SO17 1BJ, UK;2 RNA Therapeutics Institute & Department of Biochemistry & Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA01605, USACorrespondence[email protected]
View further author information
&
Jonathan K Watts1 Department of Chemistry & Institute for Life Sciences, University of Southampton, Highfield, Southampton, SO17 1BJ, UK;2 RNA Therapeutics Institute & Department of Biochemistry & Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA01605, USACorrespondence[email protected]
View further author information
Pages 2221-2242 | Published online: 29 Oct 2015

References

  • Zamecnik PC , StephensonML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl Acad. Sci. USA75, 280–284 (1978).
  • Zamecnik PC , StephensonML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl Acad. Sci. USA75, 285–288 (1978).
  • Roehr B . Fomivirsen approved for CMV retinitis. J. Int. Assoc. Physicians AIDS Care4 (10), 14–16 (1998).
  • Jones D . The long march of antisense. Nat. Rev. Drug Discov.10 (6), 401–402 (2011).
  • Watts JK , CoreyDR. Silencing disease genes in the laboratory and the clinic. J. Pathol.226, 365–379 (2012).
  • Hair P , CameronF, McKeageK. Mipomersen sodium: first global approval. Drugs73, 487–493 (2013).
  • Sharma VK , RungtaP, PrasadAK. Nucleic acid therapeutics: basic concepts and recent developments. RSC Adv.4, 16618–16631 (2014).
  • Ng EW , ShimaDT, CaliasP, CunninghamETJr, GuyerDR, AdamisAP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov.5, 123–132 (2006).
  • Deleavey GF , DamhaMJ. Designing chemically modified oligonucleotides for targeted gene silencing. Chem. Biol.19, 937–954 (2012).
  • Yu RZ , GrundyJS, GearyRS. Clinical pharmacokinetics of second generation antisense oligonucleotides. Expert Opin. Drug Metab. Toxicol.9, 169–182 (2013).
  • Shima C , SakaguchiH, GomiFet al. Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol.86, 372–376 (2008).
  • Anderson KP , FoxMC, Brown-DriverV, MartinMJ, AzadRF. Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA. Antimicrob. Agents Chemother.40, 2004–2011 (1996).
  • Apte RS . Pegaptanib sodium for the treatment of age-related macular degeneration. Expert Opin. Pharmacother.9, 499–508 (2008).
  • Kanwar JR , ShankaranarayananJS, GurudevanS, KanwarRK. Aptamer-based therapeutics of the past, present and future: from the perspective of eye-related diseases. Drug Discov. Today19, 1309–1321 (2014).
  • Shima D , CaliasP, AdamisAP. WO2005020972A2 (2012).
  • Feingold KR . Does inhibition of apolipoprotein B synthesis produce foie gras?J. Lipid Res.51, 877–878 (2010).
  • Geary RS , NorrisD, YuR, BennettCF. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv. Drug. Deliv. Rev.87, 46–51 (2015).
  • Sharma VK , SharmaRK, SinghSK. Antisense oligonucleotides: modifications and clinical trials. Med. Chem. Comm.5, 1454–1471 (2014).
  • Bennett CF , SwayzeEE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol.50, 259–293 (2010).
  • Alam MR , DixitV, KangHet al. Cellular delivery of siRNA and antisense oligonucleotides via receptor-mediated endocytosis. Expert Opin. Drug Deliv.8, 435–449 (2011).
  • Yu B , ZhaoX, LeeLJ, LeeRJ. Targeted delivery systems for oligonucleotide therapeutics. AAPS J.11, 195–203 (2009).
  • Robbins M , JudgeA, MacLachlanI. siRNA and innate immunity. Oligonucleotides19, 89–102 (2009).
  • Rautio J , KumpulainenH, HeimbachTet al. Prodrugs: design and clinical applications. Nat. Rev. Drug Discov.7, 255–270 (2008).
  • Grijalvo S , AvinoA, EritjaR. Oligonucleotide delivery: a patent review (2010 – 2013). Expert Opin. Ther. Pat.24, 801–819 (2014).
  • MacLeod AR . Antisense therapies for cancer: bridging the pharmacogenomic divide. Drug Discov, Today Ther. Strateg.10, e157 (2013).
  • Bedikian AY , GarbeC, ConryR, LebbeC, GrobJJ. Genasense Melanoma Study Group. Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low-normal serum lactate dehydrogenase: ‘The AGENDA trial’. Melanoma Res.24, 237–243 (2014).
  • Regulus. A single subcutaneous dose of 2mg/kg of RG-101, Regulus’ wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122, demonstrates 4.1 log10 mean viral load reduction as monotherapy at day 29 in patients with varied HCV genotypes and treatment history. http://ir.regulusrx.com/releasedetail.cfm?ReleaseID=877462.
  • Meade BR , GogoiK, HamilASet al. Efficient delivery of RNAi prodrugs containing reversible charge-neutralizing phosphotriester backbone modifications. Nat. Biotechnol.32, 1256–1261 (2014).
  • Zamecnik PC , GoodchildJ, TaguchiY, SarinPS. Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA. Proc. Natl Acad. Sci. USA83, 4143–4146 (1986).
  • Matsukura M , ShinozukaK, ZonGet al. Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc. Natl Acad. Sci. USA84, 7706–7710 (1987).
  • Agrawal S , GoodchildJ, CiveiraMP, ThorntonAH, SarinPS, ZamecnikPC. Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus. Proc. Natl Acad. Sci. USA85, 7079–7083 (1988).
  • Matsukura M , ZonG, ShinozukaKet al. Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc. Natl Acad. Sci. USA86, 4244–4248 (1989).
  • Mickelfield J . Backbone modification of nucleic acids: synthesis, structure and therapeutic applications. Curr. Med. Chem.8, 1157–1179 (2001).
  • Jain ML , BruicePY, SzabóIE, BruiceTC. Incorporation of positively charged linkages into DNA and RNA backbones: a novel strategy for antigene and antisense agents. Chem. Rev.112, 1284–309 (2012).
  • Eckstein F . Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic Acid Ther.24, 374–387 (2014).
  • Eckstein F . Phosphorothioate Oligodeoxynucleotides: what is their origin and what is unique about them?Antisense Nucleic Acid Drug Dev.10, 117–121 (2000).
  • Stein CA , SubasingheC, ShinozukaK, CohenJS. Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res.16, 3209–3221 (1988).
  • Geary RS . Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin. Drug Met.5, 381–391 (2009).
  • Pirollo KF , RaitA, SleerLS, ChangEH. Antisense therapeutics: from theory to clinical practice. Pharmacol. Ther.99, 55–77 (2003).
  • Lima WF , PrakashTP, MurrayHMet al. Single-stranded siRNAs activate RNAi in animals. Cell150, 883–894 (2012).
  • Hu J , LiuJ, NarayanannairKJet al. Allele-selective inhibition of mutant atrophin-1 expression by duplex and single-stranded RNAs. Biochemistry53, 4510–4518 (2014).
  • Boczkowska M , GugaP, StecWJ. Stereodefined phosphorothioate analogues of DNA: relative thermodynamic stability of the model PS-DNA/DNA and PS-DNA/RNA complexes. Biochemistry41, 12483–12487 (2002).
  • Stec WJ , CierniewskiCS, OkruszekAet al. Stereodependent inhibition of plasminogen activator inhibitor type 1 by phosphorothioate oligonucleotides: proof of sequence specificity in cell culture and in vivo rat experiments. Antisense Nucleic Acid Drug Dev.7, 567–573 (1997).
  • Koziolkiewicz M , KrakowiakA, KwinkowskiM, BoczkowskaM, StecWJ. Stereodifferentiation-the effect of P chirality of oligo(nucleoside phosphorothioates) on the activity of bacterial RNase H. Nucleic Acids Res.23, 5000–5005 (1995).
  • Gagnon KT , WattsJK. Meeting Report: 10th Annual Meeting of the Oligonucleotide Therapeutics Society. Nucleic Acid Ther.24, 428–434 (2014).
  • Mergny JL , LacroixL. Analysis of thermal melting curves. Oligonucleotides13, 515–537 (2003).
  • LeBlanc DA , MordenKM. Thermodynamic characterization of deoxyribooligonucleotide duplexes containing bulges. Biochemistry30, 4042–4047 (1991).
  • Puglisi JD , TinocoIJr. Absorbance melting curves of RNA. Methods Enzymol.180, 304–325 (1989).
  • Matveeva OV , MathewsDH, TsodikovADet al. Thermodynamic criteria for high hit rate antisense oligonucleotide design. Nucleic Acids Res.31, 4989–4994 (2003).
  • Crothers DM , ZimmBH. Theory of the melting transition of synthetic polynucleotides: evaluation of the stacking free energy. J. Mol. Biol.9, 1–9 (1964).
  • Tinoco I Jr , BorerPN, DenglerBet al. Improved estimation of secondary structure in ribonucleic acids. Nat. New Biol.246, 40–41 (1973).
  • Kierzek E , MathewsDH, CiesielskaA, TurnerDH, KierzekR. Nearest neighbor parameters for Watson–Crick complementary heteroduplexes formed between 2’-O-methyl RNA and RNA oligonucleotides. Nucleic Acids Res.34, 3609–3614 (2006).
  • Mathews DH . Using OligoWalk to identify efficient siRNA sequences. Methods Mol. Biol.629, 109–121 (2010).
  • Lu ZJ , MathewsDH. OligoWalk: an online siRNA design tool utilizing hybridization thermodynamics. Nucleic Acids Res.36 (Web Server issue), W104–W108 (2008).
  • Monia BP , LesnikEA, GonzalezCet al. Evaluation of 2’-modified oligonucleotides containing 2’-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem.268, 14514–14522 (1993).
  • Stanton R , SciabolaS, SalattoCet al. Chemical modification study of antisense gapmers. Nucleic Acid Ther.22, 344–359 (2012).
  • Seth PP , SiwkowskiA, AllersonCRet al. Short antisense oligonucleotides with novel 2’,-4’ conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J. Med. Chem.52, 10–13 (2009).
  • Ferrari N , SeguinR. Oligonucleotide inhibitors with chimeric backbone and 2-amino-2’-deoxyadenosine. PCT/CA2012/000169 (2012).
  • Sipova H , SpringerT, RejmanDet al. 5’-O-methylphosphonate nucleic acids – new modified DNAs that increase the Escherichia coli RNase H cleavage rate of hybrid duplexes. Nucleic Acids Res.42, 5378–5389 (2014).
  • Isobe H , FujinoT, YamazakiN, NiekowskiMG, NakamuraE. Triazole-linked analogue of deoxyribonucleic acid (TLDNA): design, synthesis, and double-strand formation with natural DNA. Org. Lett.10, 3729–3732 (2008).
  • Varizhuk AM , KaluzhnyDN, NovikovRAet al. Synthesis of triazole-linked oligonucleotides with high affinity to DNA complements and an analysis of their compatibility with biosystems. J. Org. Chem.78, 5964–5969 (2013).
  • Varizhuk A , ChizhovA, FlorentievV. Synthesis and hybridization data of oligonucleotide analogs with triazole internucleotide linkages, potential antiviral and antitumor agents. Bioorg. Chem.39, 127–131 (2011).
  • Périgaud C , GosselinG, LefebvreIet al. Rational design for cytosolic delivery of nucleoside monphosphates: “SATE” and “DTE” as enzyme-labile transient phosphate protecting groups. Bioorg. Med. Chem. Lett.3, 2521–2526 (1993).
  • Gao S , Dagnaes-HansenF, NielsenEJet al. The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol. Ther.17, 1225–1233 (2009).
  • Prakash TP . An overview of sugar-modified oligonucleotides from antisense therapeutics. Chem. Biodivers.8, 1616–1641 (2011).
  • Wengel J . Synthesis of 3′-C- and 4′-C-branched oligodeoxynucleotides and the development of locked nucleic acid (LNA). Acc. Chem. Res.32, 301–306 (1999).
  • Martín-Pintado N , Yahyaee-AnzahaeeM, Campos-OlivasRet al. The solution structure of double helical arabino nucleic acids (ANA and 2’F-ANA): effect of arabinoses in duplex-hairpin interconversion. Nucleic Acids Res.40, 9329–9339 (2012).
  • Bramsen JB , KjemsJ. Chemical modification of small interfering RNA. Methods Mol. Biol.721, 77–103 (2011).
  • Martínez-Montero S , DeleaveyGF, Martín-PintadoN, FakhouryJF, GonzálezC, DamhaMJ. Locked 2’-deoxy-2’,4’-difluororibo modified nucleic acids: thermal stability, structural studies, and siRNA activity. ACS Chem. Biol. doi:10.1021/acschembio.5b00218 (2015) ( Epub ahead of print).
  • Whitehead KA , DahlmanJE, LangerRS, AndersonDG. Silencing or stimulation? siRNA delivery and the immune system. Annu. Rev. Chem. Biomol. Eng.2, 77–96 (2011).
  • Kaur H , BabuBR, MaitiS. Perspectives on chemistry and therapeutic applications of locked nucleic acid (LNA). Chem. Rev.107, 4672–4697 (2007).
  • Lindow M , KauppinenS. Discovering the first microRNA-targeted drug. J. Cell Biol.199, 407–412 (2012).
  • Obad S , Dos SantosCO, PetriAet al. Silencing of microRNA families by seed-targeting tiny LNAs. Nat. Genet.43, 371–378 (2011).
  • Wahlestedt C , SalmiP, GoodLet al. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc. Natl Acad. Sci. USA97, 5633–5638 (2000).
  • Stein CA , HansenJB, LaiJet al. Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res38, e3 (2010).
  • Pedersen L , HagedornPH, LindholmMW, LindowM. A kinetic model explains why shorter and less affine enzyme-recruiting oligonucleotides can be more potent. Mol. Ther. Nucleic Acids.3, e149 (2014).
  • Zhou C , LiuY, AndaloussiM, BadgujarN, PlashkevychO, ChattopadhyayaJ. Fine tuning of electrostatics around the internucleotidic phosphate through incorporation of modified 2’,4’-carbocyclic-LNAs and -ENAs leads to significant modulation of antisense properties. J. Org. Chem.74, 118–134 (2009).
  • Morita K , HasegawaC, KanekoMet al. 2’-O,4’-C-ethylene-bridged nucleic acids (ENA): highly nuclease-resistant and thermodynamically stable oligonucleotides for antisense drug. Bioorg. Med. Chem. Lett.12, 73–76 (2002).
  • Rahman SMA , SekiS, ObikaS, YoshikawaH, MiyashitaK, ImanishiT. Design, synthesis and properties of 2’,4’-BNA(NC): a bridged nucleic acid analogue. J. Am. Chem. Soc.130, 4886–4896 (2008).
  • Giannaris P , DamhaMJ. Hybridization properties of oligoarabinonucleotides. Can. J. Chem.72, 909–918 (1994).
  • Noronha AM , WildsCJ, LokC-Net al. Synthesis and biophysical properties of arabinonucleic acids (ANA): circular dichroic spectra, melting temperature, and ribonuclease H susceptibility of ANA·RNA hybrid duplexes. Biochemistry39, 7050–7062 (2000).
  • Lima WF , NicholsJG, WuHet al. Structural requirements at the catalytic site of the heteroduplex substrate for human RNase H1 catalysis. J. Biol. Chem.279, 36317–36326 (2004).
  • Watts JK , DamhaMJ. 2’F-arabinonucleic acids (2’F-ANA) – history, properties, and new frontiers. Can. J. Chem.86, 641–656 (2008).
  • Wilds CJ , DamhaMJ. 2’-deoxy-2’-fluoro-β-D-arabinonucleosides and oligonucleotides (2’F-ANA): synthesis and physicochemical studies. Nucleic Acids Res.28, 3625–3635 (2000).
  • Ferrari N , BergeronD, Tedeschia-Let al. Characterization of antisense oligonucleotides comprising 2’-deoxy-2’-fluoro-beta-D-arabinonucleic acid (FANA): specificity, potency, and duration of activity. Ann. NY Acad. Sci.1082, 91–102 (2006).
  • Martínez-Montero S , DeleaveyGF, Dierker-ViikAet al. Synthesis and properties of 2’-deoxy-2’,4’-difluoroarabinose-modified nucleic acids. J. Org. Chem.80, 3083–3091 (2015).
  • S⊘rensen MD , Kværn⊘L, BryldTet al. Alpha-L-ribo-configured locked nucleic acid (alpha-L-LNA): synthesis and properties. J. Am. Chem. Soc.124, 2164–2176 (2002).
  • Rajwanshi VK , HakanssonAE, SorensenMDet al. The eight stereoisomers of LNA (locked nucleic acid): a remarkable family of strong RNA binding molecules. Angew. Chem. Int. Ed. Engl.39, 1656–1659 (2000).
  • Nielsen JT , SteinPC, PetersenM. NMR structure of an α-L-LNA:RNA hybrid: structural implications for RNase H recognition. Nucleic Acids Res.31, 5858–5867 (2003).
  • Frieden M , ChristensenSM, MikkelsenNDet al. Expanding the design horizon of antisense oligonucleotides with alpha-l-LNA. Nucleic Acids Res.31, 6365–6372 (2003).
  • Fluiter K , FriedenM, VreijlingJet al. On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide. Chembiochem.6, 1104–1109 (2005).
  • Seth PP , JazayeriA, YuJ, AllersonCR, BhatB, SwayzeEE. Structure activity relationships of α-L-LNA modified phosphorothioate gapmer antisense oligonucleotides in animals. Mol. Ther. Nucleic Acids18, e47 (2012).
  • Declercq R , Van AerschotA, ReadRJ, HerdewijnP, van MeerveltL. Crystal structure of double helical hexitol nucleic acids. J. Am. Chem. Soc.124 (6), 928–933 (2002).
  • Egli M , PallanPS, AllersonCRet al. Synthesis, improved antisense activity and structural rationale for the divergent RNA affinities of 3’-fluoro hexitol nucleic acid (FHNA and Ara-FHNA) modified oligonucleotides. J. Am. Chem. Soc.133, 16642–16649 (2011).
  • Van Aerschot A , MeldgaardM, SchepersGet al. Improved hybridisation potential of oligonucleotides comprising O-methylated anhydrohexitol nucleoside congeners. Nucleic Acids Res.29, 4187–4194 (2001).
  • Verbeure B , LescrinierE, WangJ, HerdewijnP. RNase H mediated cleavage of RNA by cyclohexene nucleic acid (CeNA). Nucleic Acids Res.29, 4941–4947 (2001).
  • Wang J , VerbeureB, LuytenIet al. Cyclohexene nucleic acids (CeNA): serum stable oligonucleotides that activate RNase H and increase duplex stability with complementary RNA. J. Am. Chem. Soc.122, 8595–8602 (2000).
  • Sabatino D , DamhaMJ. Oxepane nucleic acids: synthesis, characterization, and properties of oligonucleotides bearing a seven-membered carbohydrate ring. J. Am. Chem. Soc.129, 8259–8270 (2007).
  • Iversen PL . Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivation. Curr. Opin. Mol. Ther.3, 235–238 (2001).
  • Mendell JR , Rodino-KlapacLR, SahenkZet al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann. Neurol.74, 637–647 (2013).
  • Iversen PL , WarrenTK, WellsJBet al. Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections. Viruses4, 2806–2830 (2012).
  • Sarepta Therapeutics. www.sarepta.com/pipeline/avi-7100-influenza.
  • Nulf CJ , CoreyD. Intracellular inhibition of hepatitis C virus (HCV) internal ribosomal entry site (IRES)-dependent translation by peptide nucleic acids (PNAs) and locked nucleic acids (LNAs). Nucleic Acids Res.32, 3792–3798 (2004).
  • Sazani P , GemignaniF, KangSHet al. Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat. Biotechnol.20, 1228–1233 (2002).
  • Siwkowski AM , MalikL, EsauCCet al. Identification and functional validation of PNAs that inhibit murine CD40 expression by redirection of splicing. Nucleic Acids Res.32, 2695–2706 (2004).
  • Abes S , TurnerJJ, IvanovaGDet al. Efficient splicing correction by PNA conjugation to an R6-penetratin delivery peptide. Nucleic Acids Res.35, 4495–4502 (2002).
  • He G , RapireddyS, BahalR, SahuB, LyDH. Strand invasion of extended, mixed-sequence B-DNA by gammaPNAs. J. Am. Chem. Soc.131, 12088–12090 (2009).
  • Englund EA , AppellaDH. Gamma-substituted peptide nucleic acids constructed from L-lysine are a versatile scaffold for multifunctional display. Angew. Chem. Int. Edit. Engl.46, 1414–1418 (2007).
  • Herdewijn P . Heterocyclic modifications of oligonucleotide and antisense technology. Antisense Nucleic Acid Drug Dev.10, 297–310 (2000).
  • Peacock H , KannanA, BealPA, BurrowsCJ. Chemical modification of siRNA bases to probe and enhance RNA interference. J. Org. Chem.76, 7295–7300 (2011).
  • Verma S , EcksteinF. Modified oligonucleotides: synthesis and strategy for users. Annu. Rev. Biochem.67, 99–134 (1998).
  • Freier SM , AltmannKH. The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes. Nucleic Acids Res.25, 4429–4443 (1997).
  • Takeda K , AkiraS. Toll-like receptors in innate immunity. Int. Immunol.17, 1–14 (2005).
  • Dalpke A , FrankJ, PeterM, HeegK. Activation of toll-like receptor 9 by DNA from different bacterial species. Infect. Immun.74, 940–946 (2006).
  • Henry S , SteckerK, BrooksD, MonteithD, ConklinB, BennettCF. Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. J. Pharmacol. Exp. Ther.292, 468–479 (2000).
  • Sagi J , SzemzöA, OtvösL, VorlickovaM, KyprJ. Destabilization of the duplex and the high-salt Z-form of poly(dG-methyl5dC) by substitution of ethyl for the 5-methyl group. Int. J. Biol. Macromol.13, 329–336 (1991).
  • Froehler BC , WadwaniS, TerhorstTJ, GerrardSR. Oligodeoxynucleotides containing C-5 propyne analogs of 2’-deoxyuridine and 2’-deoxycytidine. Tetrahedron Lett.33, 5307–5310 (1992).
  • Wagner RW , MatteucciMD, LewiJG, GutierrezAJ, MouldsC, FroehlerBC. Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science260, 1510–1513 (1993).
  • Moulds C , LewisJG, FroehlerBCet al. Site and mechanism of antisense inhibition by C-5 propyne oligonucleotides. Biochemistry34, 5044–5053 (1995).
  • Shen L , SiwkowskiA, WancewiczEVet al. Evaluation of C-5 propynyl pyrimidine-containing oligonucleotides in vitro and in vivo. Antisense Nucleic Acid Drug Dev.13, 129–142 (2003).
  • Kumar P , ØstergaardME, BaralBet al. Synthesis and biophysical properties of C5-functionalized LNA (locked nucleic acid). J. Org. Chem.79, 5047–5061 (2014).
  • Morihiro K , HasegawaO, MoriS, TsunodaS, ObikaS. C5-azobenzene-functionalized locked nucleic acid uridine: isomerization properties, hybridization ability, and enzymatic stability. Org. Biomol. Chem.13, 5209–5214 (2015).
  • Guenther DC , KumarP, AndersonBA, HrdlickaPJ. C5-amino acid functionalized LNA: positively poised for antisense applications. Chem. Commun. (Camb.)50, 9007–9009 (2014).
  • Kaura M , GuentherDC, HrdlickaPJ. Carbohydrate-functionalized locked nucleic acids: oligonucleotides with extraordinary binding affinity, target specificity, and enzymatic stability. Org. Lett.16, 3308–3311 (2014).
  • Flanagan WM , WagnerRW, GrantD, LinKY, MatteucciMD. Cellular penetration and antisense activity by a phenoxazine-substituted heptanucleotide. Nat. Biotechnol.17, 48–52 (1999).
  • Lin K-Y , MatteucciMD. A cytosine analog capable of clamp-like binding to a guanine in helical nucleic acids. J. Am. Chem. Soc.120, 8531–8532 (1998).
  • Wilds CJ , MaierMA, TereshkoV, ManoharanM, EgliM. Direct observation of a cytosine analogue that forms five hydrogen bonds to guanosine: guanidino G-clamp. Angew. Chem. Int. Ed. Engl.41, 115–117 (2002).
  • Wilds CJ , MaierMA, ManoharanM, EgliM. Structural basis for recognition of guanosine by a synthetic tricyclic cytosine analogue: guanidinium G-clamp. Helv. Chim. Acta86, 966–978 (2003).
  • Gryaznov SM , SchultzRG. Stabilization of DNA:DNA and DNA:RNA duplex by substitution of 2-deoxyadenosine with 2-deoxy-2-aminoadenosine. Tetrahedron Lett.36, 2489–2492 (1994).
  • Müller RH , ShegokarR, KeckCM. 20 years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications. Curr. Drug Discov. Technol.8, 207–227 (2011).
  • Ballarín-González B , HowardKA. Polycation-based nanoparticle delivery of RNAi therapeutics: adverse effects and solutions. Adv. Drug Deliv. Rev.64, 1717–1729 (2012).
  • Kichler A , ZaunerW, OgrisM, WagnerE. Influence of the DNA complexation medium on the transfection efficiency of lipospermine/DNA particles. Gene Ther.5, 855–860 (1998).
  • Dalby B , CatesS, HarrisAet al. Advanced transfection with Lipofectamine 2000 reagent: primary neurons, siRNA, and highthroughput applications. Methods33, 95–103 (2004).
  • Draghici B , IliesMA. Synthetic nucleic acid delivery systems: present and perspectives. J. Med. Chem.58, 4091–4130 (2015).
  • Shim G . Application of cationic liposomes for delivery of nucleic acids. Asian J. Pharm. Sci.8, 72–80 (2013).
  • Ma B , ZhangS, JiangH, ZhaoB, LvH. Lipoplex morphologies and their influences on transfection efficiency in gene delivery. J. Control Release123, 184–194 (2007).
  • Rädler JO , KoltoverI, SaldittT, SafinyaCR. Structure of DNa–cationic liposome complexes: DNA intercalation in multilamellar membranes in distinct interhelical packing regimes. Science275, 810–814 (1997).
  • Koltover I , SaldittT, RädlerJO, SafinyaCR. An inverted hexagonal phase of cationic liposome–DNA complexes related to DNA release and delivery. Science281, 78–81 (1998).
  • Leal C , BouxseinNF, EwertKK, SafinyaCR. Highly efficient gene silencing activity of siRNA embedded in a nanostructured gyroid cubic lipid matrix. J. Am. Chem. Soc.132, 16841–16847 (2010).
  • Leal C , EwertKK, ShiraziRS, BouxseinNF, SafinyaCR. Nanogyroids incorporating multivalent lipids: enhanced membrane charge density and pore forming ability for gene silencing. Langmuir27, 7691–7697 (2011).
  • Ewert K , AhmadA, EvansHM, SchmidtHW, SafinyaCR. Efficient synthesis and cell-transfection properties of a new multivalent cationic lipid for nonviral gene delivery. J. Med. Chem.45, 5023–5029 (2002).
  • Lin AJ , SlackNL, AhmadA, GeorgeCX, SamuelCE, SafinyaCR. Three-dimensional imaging of lipid gene-carriers: membrane charge density controls universal transfection behavior in lamellar cationic liposome-DNA complexes. Biophys. J.84, 3307–3316 (2003).
  • Avanti® Polar Lipids, Inc. www.avantilipids.com/index.php?option=com_content&view=article&id=2422&Itemid=521&catnumber=890000.
  • Aliabadi HM , LandryB, SunC, TangT, UludağH. Supramolecular assemblies in functional siRNA delivery: where do we stand?Biomaterials33, 2546–2569 (2012).
  • Daka A , PeerD. RNAi-based nanomedicines for targeted personalized therapy. Adv. Drug Deliv. Rev.64, 1508–1521 (2012).
  • Mui BL , TamYK, JayaramanMet al. Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles. Mol. Ther. Nucleic Acids2, e139 (2013).
  • Ogris M , BrunnerS, SchüllerS, KircheisR, WagnerE. PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther.6, 595–605 (1999).
  • Maeda H , WuJ, SawaT, MatsumuraY, HoriK. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release65, 271–284 (2000).
  • Morrissey DV , LockridgeJA, ShawLet al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol.23, 1002–1007 (2005).
  • Zimmermann TS , LeeAC, AkincAet al. RNAi-mediated gene silencing in non-human primates. Nature441, 111–114 (2006).
  • Semple SC , AkincA, ChenJet al. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol.28, 172–176 (2010).
  • Geall AJ , VermaA, OttenGRet al. Nonviral delivery of self-amplifying RNA vaccines. Proc. Natl Acad. Sci. USA109, 14604–14609 (2012).
  • Ozcan G , OzpolatB, ColemanRL, SoodAK, Lopez-BeresteinG. Preclinical and clinical development of siRNa-based therapeutics. Adv. Drug Deliv. Rev.87, 108–119 (2015).
  • Ganta S , DevalapallyH, ShahiwalaA, AmijiM. A review of stimuli-responsive nanocarriers for drug and gene delivery. J. Control. Release126, 187–204 (2008).
  • Niu Y , SunL, CrooksRM. Determination of the intrinsic proton binding constants for poly(amidoamine) dendrimers via potentiometric pH titration. Macromolecules36, 5725–5731 (2003).
  • Liang W , LamJKW. Endosomal escape pathways for non-viral nucleic acid delivery systems. In : Molecular Regulation of Endocytosis. CeresaB ( Ed.). InTech, Croatia, 421–467 (2012).
  • Yessine M-A , MeierC, PetereitH-U, LerouxJ-C. On the role of methacrylic acid copolymers in the intracellular delivery of antisense oligonucleotides. Eur. J. Pharm. Biopharm.63, 1–10 (2006).
  • Convertine AJ , DiabC, PrieveMet al. pH-responsive polymeric micelle carriers for siRNA drugs. Biomacromolecules11, 2904–2911 (2011).
  • Kim SH , JeongJH, MokH, LeeSH, KimSW, ParkTG. Folate receptor targeted delivery of polyelectrolyte complex micelles prepared from ODN–PEG–folate conjugate and cationic lipids. Biotechnol. Prog.23, 232–237 (2007).
  • Palanca-Wessels MC , ConvertineAJ, Cutler-StromRet al. Anti-CD22 antibody targeting of pH-responsive micelles enhances small interfering RNA delivery and gene silencing in lymphoma cells. Mol. Ther.19, 1529–1537 (2011).
  • Oishi M , NagasakiY, ItakaK, NishiyamaN, KataokaK. Lactosylated poly(ethylene glycol)–siRNA conjugate through acid-labile β-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepatoma cells. J. Am. Chem. Soc.127, 1624–1625 (2005).
  • Sethuraman V , LeeM, BaeY. A biodegradable pH-sensitive micelle system for targeting acidic solid tumors. Pharm. Res.25, 657–666 (2008).
  • Farokhzad OC , KarpJM, LangerR. Nanoparticle–aptamer bioconjugates for cancer targeting. Expert Opin. Drug Deliv.3, 311–324 (2006).
  • Petrova NS , ChernikovIV, MeschaninovaMIet al. Carrier-free cellular uptake and the gene-silencing activity of the lipophilic siRNAs is strongly affected by the length of the linker between siRNA and lipophilic group. Nucleic Acids Res.40, 2330–2344 (2012).
  • AVI Biopharma, Inc. WO2012150960 A1 (2012).
  • Zhu H , LiJ, ZhangXB, YeM, TanW. Nucleic acid aptamer-mediated drug delivery for targeted cancer therapy. Chem Med Chem.10, 39–45 (2015).
  • Ristau BT , O'KeefeDS, BacichDJ. The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research. Urol. Oncol.32, 272–279 (2014).
  • McNamara JO 2nd , AndrechekEO, WangYet al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol.24, 1005–1015 (2006).
  • Chu TC , TwuKY, EllingtonAD, LevyM. Aptamer mediated siRNA delivery. Nucleic Acids Res.34, e73 (2006).
  • Zhou J , SwiderskiP, LiHet al. Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res.37, 3094–3109 (2009).
  • Dassie JP , LiuXY, ThomasGSet al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMa-expressing tumors. Nat. Biotech.27, 839–846 (2009).
  • Grewal PK . The Ashwell–Morell receptor. Methods Enzymol.479, 223–241 (2010).
  • Nair JK , WilloughbyJLS, ChanAet al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi- mediated gene silencing. J. Am. Chem. Soc.136, 16958–16961 (2014).
  • Rajeev KG , NairJK, JayaramanMet al. Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo. Chembiochem16, 903–908 (2015).
  • Matsuda S , KeiserK, NairJKet al. siRNA conjugates carrying sequentially assembled trivalent nacetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes. ACS Chem. Biol.10, 1181–1187 (2015).
  • Prakash TP , GrahamMJ, YuJet al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res.42, 8796–8807 (2014).
  • Østergaard ME , YuJ, KinbergerGAet al. Efficient synthesis and biological evaluation of 5’-GalNAc conjugated antisense oligonucleotides. Bioconjug. Chem.26 (8), 1451–1455 (2015).
  • Patwa A , GissotA, BestelI, BarthelemyP. Hybrid lipid oligonucleotide conjugates: synthesis, self-assemblies and biomedical applications. Chem. Soc. Rev.40, 5844–5854 (2011).
  • Lorenz C , HadwigerP, JohnM, VornlocherHP, UnverzagtC. Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg. Med. Chem. Lett.14, 4975–4977 (2004).
  • Sylentis SAU . Sphingosine-bound siRNA. US2012142765 A1 (2012).
  • Wolfrum C , ShiS, JayaprakashKNet al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotechnol.25, 1149–1157 (2007).
  • Trajkovski M , HausserJ, SoutschekJet al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature474, 649–653 (2011).
  • Nishina K , UnnoT, UnoYet al. Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. Mol. Ther.16, 734–740 (2008).
  • Nishina T , NumataJ, NishinaKet al. Chimeric antisense oligonucleotide conjugated to α-tocopherol. Mol. Ther. Nucleic Acids.4, e220 (2015).
  • Heitz F , MorrisMC, DivitaG. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br. J. Pharmacol.157, 195–206 (2009).
  • Lundberg P , El-AndaloussiS, SutluT, JohanssonH, LangelU. Delivery of short interfering RNA using endosomolytic cellpenetrating peptides. FASEB J.21, 2664–2671 (2007).
  • Fei L , RenL, ZaroJL, ShenW-C. The influence of net charge and charge distribution on cellular uptake and cytosolic localization of arginine-rich peptides. J. Drug Target19, 675–680 (2011).
  • Lebleu B , MoultonHMet al. Cell penetrating peptide conjugates of steric block oligonucleotides. Adv. Drug Deliv. Rev.60, 517–529 (2008).
  • Goyenvalle A , BabbsA, PowellDet al. Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping. Mol. Ther.18, 198–205 (2009).
  • Koppelhus U , ShiraishiT, ZacharV, PankratovaS, NielsenPE. Improved cellular activity of antisense peptide nucleic acids by conjugation to a cationic peptide–lipid (CatLip) domain. Bioconjugate Chem.19, 1526–1534 (2008).
  • Poillot C , BichraouiH, TisseyreCet al. Small efficient cell-penetrating peptides derived from scorpion toxin maurocalcine. J. Biol. Chem.287, 17331–17342 (2012).
  • Betts C , SalehAF, ArzumanovAAet al. Pip6-PMO, a new generation of peptide–oligonucleotide conjugates with improved cardiac exon skipping activity for DMD treatment. Mol. Ther. Nucleic Acids1, e38 (2012).
  • Mirkin CA , LetsingerRL, MucicRC, StorhoffJJ. A DNA-based method for rationally assembling nanoparticles into macroscopic materials. Nature382, 607–609 (1996).
  • Rosi NL , GiljohannDA, ThaxtonCS, Lytton-JeanAK, HanMS, MirkinCA. Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science312, 1027–1030 (2006).
  • Seferos DS , PrigodichAE, GiljohannDA, PatelPC, MirkinCA. Polyvalent DNA nanoparticle conjugates stabilize nucleic acids. Nano Lett.9, 308–311 (2009).
  • Lytton-Jean AK , LangerR, AndersonDG. Five years of siRNA delivery: spotlight on gold nanoparticles. Small7, 1932–1937 (2011).
  • Giljohann DA , SeferosDS, PatelPC, MillstoneJE, RosiNL, MirkinCA. Oligonucleotide loading determines cellular uptake of DNa-modified gold nanoparticles. Nano Lett.7, 3818–3821 (2007).
  • Giljohann DA , SeferosDS, PrigodichAE, PatelPC, MirkinCA. Gene regulation with polyvalent siRNa-nanoparticle conjugates. J. Am. Chem. Soc.131, 2072–2073 (2009).
  • Giljohann DA , SeferosDS, DanielWL, MassichMD, PatelPC, MirkinCA. Gold nanoparticles for biology and medicine. Angew. Chem. Int. Ed. Engl.49, 3280–3294 (2010).
  • Patel PC , GiljohannDA, DanielWL, ZhengD, PrigodichAE, MirkinCA. Scavenger receptors mediate cellular uptake of polyvalent oligonucleotide-functionalized gold nanoparticles. Bioconjug. Chem.21, 2250–2256 (2010).
  • Choi CH , HaoL, NarayanSP, AuyeungE, MirkinCA. Mechanism for the endocytosis of spherical nucleic acid nanoparticle conjugates. Proc. Natl Acad. Sci. USA110, 7625–7630 (2013).
  • Zhang K , HaoL, HurstSJ, MirkinCA. Antibody-linked spherical nucleic acids for cellular targeting. J. Am. Chem. Soc.134, 16488–16491 (2012).
  • Lee JS , Lytton-JeanAK, HurstSJ, MirkinCA. Silver nanoparticle–oligonucleotide conjugates based on DNA with triple cyclic disulfide moieties. Nano Lett.7, 2112–2115 (2007).
  • Hilliard LR , ZhaoXJ, TanWH. Immobilization of oligonucleotides onto silica nanoparticles for DNA hybridization studies. Anal. Chim. Acta470, 51–56 (2002).
  • Cutler JI , ZhengD, XuX, GiljohannDA, MirkinCA. Polyvalent oligonucleotide iron oxide nanoparticle “click” conjugates. Nano Lett.10, 1477–1480 (2010).
  • Medintz IL , BertiL, PonsTet al. A reactive peptidic linker for self-assembling hybrid quantum dot-DNA bioconjugates. Nano Lett.7, 1741–1748 (2007).
  • Williams SC . Spherical nucleic acids: a whole new ball game. Proc. Natl Acad. Sci. USA110, 13231–13233 (2013).
  • Banga RJ , ChernyakN, NarayanSP, NguyenST, MirkinCA. Liposomal spherical nucleic acids. J. Am. Chem. Soc.136, 9866–9869 (2014).
  • Radovic-Moreno AF , ChernyakN, MaderCCet al. Immunomodulatory spherical nucleic acids. Proc. Natl Acad. Sci. USA112, 3892–3897 (2015).
  • Jinek M , ChylinskiK, FonfaraI, HauerM, DoudnaJA, CharpentierE. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science337, 816–821 (2012).
  • O'Connell MR , OakesBL, SternbergSH, East-SeletskyA, KaplanM, DoudnaJA. Programmable RNA recognition and cleavage by CRISPR/Cas9. Nature516, 263–266 (2014).
  • Barrangou R , BirminghamA, WiemannS, BeijersbergenRL, HornungV, SmithAV. Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interference. Nucleic Acids Res.43, 3407–3419 (2015).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.